Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06542536
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-05
Brief Title:
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Investigation of Tolerability Safety and Pharmacokinetic Properties of a Single Oral Dose of Monlunabant in Male Japanese and Caucasian Participants With Normal Body Weight
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose The aim of this study is to see if the new medicine is safe and how it works in the participants body Oral monlunabant is a new medicine which cannot be prescribed by doctors but has previously been tested in humans The participant will either get monlunabant or placebo or a combination of both Which treatment the participant get is decided by chance The study will last for about 49 days in total
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None